Printer Friendly

OSTEOTECH EXPANDS MARKETING PROGRAM AND IS AWARDED GRAFTON PROCESSED BONE GEL PATENT

           OSTEOTECH EXPANDS MARKETING PROGRAM AND IS AWARDED
                   GRAFTON PROCESSED BONE GEL PATENT
    SHREWSBURY, N.J., Dec. 17 /PRNewswire/ -- Osteotech, Inc. (NASDAQ: OSTE) announced today that it was expanding its marketing force significantly to launch Grafton(TM) processed bone gel into the orthopedic and neurosurgical markets.  The Grafton gel aids in the formation of new bone thus assisting repair.  The gel, which is distributed by the company's not for profit customers, was first introduced into the oral maxillofacial, dental and periodontal markets in August 1991, but Osteotech believes the major market opportunity is the repair of orthopedic and spinal injuries.
    Roger Stikeleather, vice president of marketing, reported that Osteotech was "doubling its direct marketing force from 10 to 20 representatives in preparation for the Grafton gel market expansion, the first major marketing program for the company."
    Osteotech also announced that the United States Patent and Trademark office awarded U.S. Patent No. 5,073,373 covering the unique formulation of the Grafton processed bone gel.  "Our strong proprietary position was one of the important elements in our decision to invest heavily in marketing of the Grafton gel in 1992.  The anticipated cost associated with the expansion of the direct marketing force will likely result in lower earnings for at least the first two quarters of 1992," said Patrick McBrayer, president and chief executive officer of Osteotech. McBrayer further noted that, "the Grafton gel's unique capability to aid in bone formation has the potential to markedly increase Osteotech's sales and earnings in this decade and provide a launching pad for other products now in development."
    Osteotech is leading processor of human bone and bone connective tissue for transplantation, and an innovator in the development of tissue related biomaterials and pharmaceutical delivery systems for musculoskeletal surgery.
    -0-         12/17/91
    /CONTACT:  Michael J. Jeffries of Osteotech, 908-542-2800/
    (OSTE) CO:  Osteotech, Inc. ST:  New Jersey IN:  MTC SU: SM-SH -- NY012 -- 2845 12/17/91 09:40 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 17, 1991
Words:323
Previous Article:ARCHER COMMUNICATIONS RECEIVES NOTIFICATION BY THE U.S. PATENT AND TRADEMARK OFFICE IN RESPECT TO QSOUND TECHNOLOGY
Next Article:ADVANCED MAGNETICS, INC. CHANGES STOCK SYMBOL
Topics:


Related Articles
OSTEOTECH RECEIVES U.S. PATENT FOR A UNIQUE COATING FOR IMPLANTS
/C O R R E C T I O N -- OSTEOTECH/
OSTEOTECH INTRODUCES GRAFTON DBM FLEX, A NEW FLEXIBLE FORM OF BANKED HUMAN BONE
Osteotech Obtains Consent Injunction Against Biosystems of New England
Osteotech Files Patent Infringement Suit
Osteotech Reports Second Quarter Revenues Increased 43%; Net Income Increased 73%
Osteotech Amends GenSci Patent Infringement Suit Adds DePuy, Inc. and DePuy Motech, Inc.
Osteotech amends GenSci patent infringement suit adds DePuy
Osteotech announces development in lawsuit against GenSci.
Osteotech Announces Publication of an Industry First, Prospective Randomized Clinical Trial With Demineralized Bone Matrix in a Carrier; Grafton(R)...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters